Newly Activated Clinical Trials

The following studies were recently activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office.

Click the study links below to learn details regarding the study on For more information or questions about a study, email or call 312-355-5112.

Protocol Title: HCRN-BRE17-141: An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in Triple Positive Breast Cancers

PI: Oana Danciu, MD
Sponsor: Hoosier Cancer Research Network 

Protocol Title: : INCAGN2385-203: A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1 Positive (CPS >/-1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

PI: Lawrence Feldman, MD
Sponsor: Incyte Corporation 

Translate »